Can You Use GAPDH and ACTB Together as Reference Genes?

Yes, you can use GAPDH and ACTB together as reference genes — and in many experimental contexts, using two reference genes is better than relying on one. But the real question isn't whether you can pair them; it's whether they're actually stable in your system. These two genes are the most commonly used references in qPCR, which means they're also the most commonly misused. They co-appear in thousands of papers not because someone validated the pair, but because they were the default primers sitting in the freezer.

The short version: if you've run a stability analysis (geNorm, NormFinder, or BestKeeper) and both genes rank well in your tissue, treatment, and species, then averaging their Ct values to create a composite reference is a solid approach. It reduces the noise inherent in single-gene normalization and gives your ΔCt calculation a more reliable denominator. But if you're working with adipocytes, hypoxic conditions, serum-starved cells, or comparing across metabolically distinct tissues, GAPDH is very likely regulated — and pairing it with ACTB won't fix that problem. It'll just dilute the error while still biasing your results.

Why Two Reference Genes Beat One

The logic is straightforward. Any single reference gene can fluctuate by 0.3–0.5 Ct across biological replicates due to genuine expression variation, not just technical noise. When you normalize your gene of interest (GOI) to a single reference, that fluctuation feeds directly into your ΔCt — and since fold change is exponential (2^-ΔΔCt), a 0.5 Ct wobble in your reference gene translates to a ~1.4-fold error in your reported expression. Averaging two stable reference genes shrinks that variance.

The standard approach is geometric averaging, as described by Vandesompele et al. (2002) in the geNorm paper. You don't simply average the raw Ct values of GAPDH and ACTB. Instead, you convert each to a relative quantity (using the sample with the lowest Ct as calibrator, or using efficiency-corrected quantities), then take the geometric mean of those quantities to produce a normalization factor. This normalization factor replaces the single reference gene Ct in your ΔCt calculation.

Practically, if your GAPDH Ct is 18.5 and your ACTB Ct is 17.2 in a given sample, you don't just average those to 17.85. The Ct values are on a log scale, so arithmetic averaging of raw Cts is a rough approximation at best. Convert to linear scale first, normalize, geometric-mean, then proceed.

Most analysis software — including the CFX Maestro for the CFX96 and the QuantStudio Design & Analysis Software — supports multi-reference normalization. If yours doesn't, or if you want to skip the manual spreadsheet work, VoilaPCR handles geometric averaging of multiple reference genes automatically when you upload your run file.

The Real Problem: Correlated Instability

Here's where the GAPDH + ACTB pair gets dicey. Both genes are involved in core cellular metabolism and cytoskeletal structure, respectively, but both are also responsive to conditions that broadly affect cell physiology. The danger isn't that one drifts — it's that they drift together.

Consider these well-documented scenarios:

• Hypoxia: GAPDH is a direct HIF-1α target. Its expression can increase 2–4 fold under hypoxic conditions. ACTB is more stable under hypoxia, but if you're averaging the two, the upregulation of GAPDH still pulls your normalization factor and compresses the apparent fold change of your GOI.
• Adipogenesis / lipogenesis: GAPDH participates in glycolysis and its expression shifts during differentiation of 3T3-L1 cells or primary adipocytes. This has been documented repeatedly (Barber et al., 2005).
• Serum starvation or cell cycle arrest: Both GAPDH and ACTB can shift during growth arrest, though the direction and magnitude depend on cell type.
• Cross-tissue comparisons: If you're comparing expression in liver vs. brain vs. skeletal muscle, both genes can vary by 2+ Ct across tissues. They're not normalizing anything — they're adding structured noise.

The fundamental issue is that GAPDH and ACTB are not independently regulated in many perturbations. When two reference genes are affected by the same biological variable, pairing them doesn't provide the error correction you think it does. You've essentially got two correlated measurements masquerading as independent validation.

How to Actually Validate the Pair

If you want to use GAPDH and ACTB together, validate them. This isn't optional — it's the minimum standard expected by journals like Nucleic Acids Research and enforced by the MIQE guidelines (Bustin et al., 2009). Here's a practical approach:

1. Pick 4–6 candidate reference genes. Start with GAPDH, ACTB, and add HPRT1, B2M, RPLP0 (also called 36B4), and TBP. If you're working in mouse, Rpl13a and Ywhaz are worth including. Having more candidates gives the algorithms something to work with.

2. Run your candidates across your actual experimental conditions. This means treated vs. untreated, all time points, all tissue types — whatever groups will appear in your final dataset. Use 3–5 biological replicates per group. Run in technical duplicate or triplicate (CV should be <0.5 Ct between technical replicates).

3. Analyze with geNorm, NormFinder, or BestKeeper. These are the three established algorithms:

   • geNorm (Vandesompele et al., 2002) calculates pairwise variation (M value) and identifies the most stable pair. An M value below 0.5 is considered stable for homogeneous samples; below 1.0 for heterogeneous samples (e.g., different tissues).
   • NormFinder (Andersen et al., 2004) accounts for inter-group variation and can flag genes that appear stable overall but differ systematically between your experimental groups.
   • BestKeeper (Pfaffl et al., 2004) works directly on Ct values and calculates SD-based stability. An SD above 1.0 suggests the gene is too variable.

4. Check the geNorm V value. geNorm also calculates the pairwise variation V(n/n+1) to determine the optimal number of reference genes. If V2/3 is below 0.15, two reference genes are sufficient. If it's above 0.15, you may need three.

5. Look at the actual Ct ranges. Even if an algorithm says GAPDH and ACTB are your best pair, look at the raw data. If GAPDH Ct ranges from 17.0 to 19.5 across your experimental groups while ACTB ranges from 16.5 to 17.3, that tells you something the stability metric might smooth over. A stable reference gene should have a Ct range of <1.0 across all your conditions, ideally <0.5.

If GAPDH and ACTB come out on top after this analysis — great, use them with confidence. If they don't, use whatever does, even if it's TBP and HPRT1 and nobody in your subfield has heard of that combination.

What If You've Already Collected Data with Only GAPDH and ACTB?

This happens constantly. You designed the experiment, ran 96-well plates on the QuantStudio 5, and now your PI or a reviewer is asking about reference gene validation. A few options:

• Check stability post hoc. You can still calculate the geNorm M value and NormFinder stability from your existing GAPDH and ACTB data across samples. You won't be able to compare against other candidates, but you can at least confirm that these two genes are stable within your dataset. If their M values are reasonable (<0.5 for cell lines, <1.0 for tissues), you can report that.
• Normalize to each one separately and compare. If your biological conclusions hold regardless of whether you normalize to GAPDH alone, ACTB alone, or the geometric mean of both, that's reassuring. If the results flip depending on which reference you use, you have a reference gene problem that averaging won't fix.
• Be transparent. In your methods, state which reference genes you used, report their Ct ranges and stability values, and acknowledge the limitation if you didn't run a full panel. Reviewers respect honesty more than hand-waving.

Better Pairs to Consider

If you're still at the planning stage and want reference gene combinations that tend to outperform GAPDH + ACTB in stability analyses, here are some that frequently rank well:

• Human cell lines (non-metabolic perturbations): HPRT1 + TBP or RPLP0 + B2M
• Mouse tissues: Hprt + Tbp or Rplp0 + Actb (yes, Actb can work in mice when the perturbation isn't cytoskeletal)
• Tumor vs. normal tissue: TBP + PPIA — both tend to be more stable than GAPDH or ACTB across malignant and non-malignant samples
• Immune cell activation: HPRT1 + RPLP0 — GAPDH and ACTB both shift during T cell activation

These are generalizations. Your mileage will vary by species, cell type, and treatment. There is no universal reference gene, which is exactly why validation exists.

The Bottom Line

Using GAPDH and ACTB together is fine — if you've shown they're stable in your system. Two validated reference genes will always give you tighter normalization than one. But "validated" means you ran a stability analysis with actual candidates, not that you assumed stability because everyone uses these genes. The fifteen minutes it takes to add HPRT1, TBP, and B2M to your plate layout could save you from a reviewer asking you to repeat the entire experiment with proper controls.